The Indian Patent Office’s rejection of a patent application for a combination of three tuberculosis (TB) medicines — bedaquiline, pretomanid and linezolid, collectively known as BPaL — has been welcomed by experts as a major step towards making treatment for drug-resistant TB more affordable and accessible.
The application was filed by the US-based Global Alliance for TB Drug Development (TB Alliance). Its rejection means that the company cannot use this particular patent application to claim exclusive rights over the combination in India. This could allow more manufacturers to produce the medicines, encouraging competition and potentially bringing down prices.
The decision follows two formal objections, known as pre-grant oppositions, filed in 2020. Such oppositions allow individuals or organisations to challenge a patent application before it is granted.…